Ashley Burriss, NP
Nurse Practitioner · Greenville, SCNPI 1558892901
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (37.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 61.1% of it on its own, with 39 other manufacturers making up the rest. 2025 is the largest year on record at $6,558, more than ten times the $24 reported in 2021. Among nurse practitioner clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 122 payments — averaging $67.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Genmab U.S., Inc.$683
- Astellas Pharma US Inc$508
- Incyte Corporation$248
- Syndax Pharmaceuticals, Inc.$187
- Daiichi Sankyo Inc.$160
- plus $1K from 34 others
What the payments were for
- Consulting fees$2,25827%
- Travel & lodging$3,06437%
- Food & beverage$2,60232%
- Education$2873%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $5,018 |
| Genmab U.S., Inc. | 1 | $683 |
| Astellas Pharma US Inc | 20 | $508 |
| Incyte Corporation | 5 | $248 |
| Syndax Pharmaceuticals, Inc. | 2 | $187 |
| Daiichi Sankyo Inc. | 8 | $160 |
| Novartis | 6 | $155 |
| Merck | 5 | $117 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| Lilly USA, LLC | 5 | $103 |
| Johnson & Johnson | 5 | $103 |
| Bayer | 3 | $78 |
| Bristol Myers Squibb | 3 | $55 |
| Jazz Pharmaceuticals Inc. | 3 | $53 |
| AstraZeneca | 3 | $52 |
| EMD Serono, Inc. | 1 | $50 |
| Adaptive Biotechnologies Corporation | 3 | $47 |
| Karyopharm Therapeutics Inc. | 3 | $38 |
| Pharmacosmos Therapeutics Inc. | 2 | $38 |
| Eisai Inc. | 2 | $30 |
| Tersera Therapeutics LLC | 1 | $26 |
| GSK | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Pfizer | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Geron Corporation | 1 | $20 |
| Seagen Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $18 |
| Nuvation Bio Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $16 |
| Beigene USA, Inc. | 1 | $16 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,210 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 57 | $1,033,455 |
| PomalystPomalidomide | 36 | $764,554 |
| Lenalidomide | 30 | $437,468 |
| BrukinsaZanubrutinib | 20 | $298,340 |
| VenclextaVenetoclax | 20 | $172,396 |
| OrgovyxRelugolix | 11 | $28,786 |
| EliquisApixaban | 18 | $14,528 |
| Dexamethasone | 62 | $2,194 |
| ValacyclovirValacyclovir Hcl | 35 | $1,659 |
| Acyclovir | 109 | $1,532 |
| Fluconazole | 42 | $1,448 |
| Ondansetron Hcl | 74 | $780 |
| Potassium Chloride | 27 | $575 |
| Levofloxacin | 75 | $544 |
| Klor-Con M20Potassium Chloride | 15 | $429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $55 | $1,033,45557 claims |
| Beigene USA, Inc.Brukinsa | $16 | $298,34020 claims |
| AbbVieVenclexta | $5,018 | $172,39620 claims |
| PfizerEliquis | $23 | $14,52818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in South Carolina.
Other nurse practitioner in Greenville
- David WiltGreenville$90K
- Mae BurtonGreenville$21K
- Deborah MooreGreenville$12K
- Cindy LoebGreenville$9K
- Kristina AldrichGreenville$7K
- Whitney ReedCharleston$54K
- Mary JohnsonCharleston$34K
- Amanda HareCharleston$30K
- Kellie McLainCharleston$28K
- Colleen BoydSummerville$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.